Literature DB >> 9388062

Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.

J Qian1, R B Jenkins, D G Bostwick.   

Abstract

Grading of the cribriform pattern of prostate cancer is controversial, and the genetic changes are largely unknown. Furthermore, the pathogenetic relationship between the cribriform pattern of high-grade prostatic intraepithelial neoplasia (PIN) and cribriform carcinoma is poorly understood. We used fluorescence in situ hybridization with centromere-specific probes for chromosomes 7, 8, 10, 12, and Y and a region-specific probe for c-myc to evaluate genetic changes in matched foci of high-grade PIN (48 foci) and prostatic carcinoma (71 foci) in 25 whole-mount radical prostatectomy specimens from patients with metastatic cancer. These cases included 10 foci of cribriform PIN and 10 foci of cribriform cancer. Numeric chromosomal anomalies were found in 67 and 68% of the high-grade PIN and carcinoma foci, respectively. Extra copies of the c-myc gene were identified in 52 and 44% of the high-grade PIN and carcinoma foci, respectively. The cribriform pattern of cancer had a higher percentage of foci with gain of chromosomes 7, 12, and Y, loss of chromosome 8, and extra copies of c-myc gene than other Gleason Primary Patterns 3 and 4; there was no difference, however, for all paired comparisons of genetic changes between the cribriform pattern of cancer and Gleason Primary Pattern 5 cancer. Cribriform PIN and cribriform cancer generally exhibited similar anomalies, although the percentage of foci with gain of chromosomes 10 and 12 was higher in cribriform cancer. Our results indicate that the cribriform pattern of prostate cancer shares genetic changes with Gleason Primary Pattern 5 and that both contain more genetic changes than the cribriform pattern of PIN. These findings suggest that the cribriform pattern of prostate cancer has biologic similarity with Gleason Pattern 5 carcinoma and that the cribriform pattern of PIN is closely associated with the cribriform pattern of prostatic carcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9388062

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  30 in total

1.  Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Authors:  Trevor A Flood; Nicola Schieda; Daniel T Keefe; Rodney H Breau; Chris Morash; Kevin Hogan; Eric C Belanger; Kien T Mai; Susan J Robertson
Journal:  Virchows Arch       Date:  2016-07-10       Impact factor: 4.064

Review 2.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

3.  Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.

Authors:  Carmela Ciccarelli; Agnese Di Rocco; Giovanni Luca Gravina; Annunziata Mauro; Claudio Festuccia; Andrea Del Fattore; Paolo Berardinelli; Francesca De Felice; Daniela Musio; Marina Bouché; Vincenzo Tombolini; Bianca Maria Zani; Francesco Marampon
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-29       Impact factor: 4.553

4.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.

Authors:  Juan-Miguel Mosquera; Sven Perner; Elizabeth M Genega; Martin Sanda; Matthias D Hofer; Kirsten D Mertz; Pamela L Paris; Jeff Simko; Tarek A Bismar; Gustavo Ayala; Rajal B Shah; Massimo Loda; Mark A Rubin
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

5.  Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.

Authors:  Jonathan D Lee; Jinfang Zhang; Shu-Yu Lin; Yu-Ru Lee; Ming Chen; Tian-Min Fu; Hao Chen; Tomoki Ishikawa; Shang-Yin Chiang; Jesse Katon; Yang Zhang; Yulia V Shulga; Assaf C Bester; Jacqueline Fung; Emanuele Monteleone; Lixin Wan; Chen Shen; Chih-Hung Hsu; Antonella Papa; John G Clohessy; Julie Teruya-Feldstein; Suresh Jain; Hao Wu; Lydia Matesic; Ruey-Hwa Chen; Wenyi Wei; Pier Paolo Pandolfi
Journal:  Science       Date:  2019-05-17       Impact factor: 47.728

6.  Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate.

Authors:  Krishna B Singh; Eun-Ryeong Hahm; Lora H Rigatti; Daniel P Normolle; Jian-Min Yuan; Shivendra V Singh
Journal:  Cancer Prev Res (Phila)       Date:  2018-03-15

7.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Robert B Jenkins; Fusheng Lan; Chi Van Dang; Jessica L Hicks; James Morgan; Toby C Cornish; Siobhan Sutcliffe; William B Isaacs; Jun Luo; Angelo M De Marzo
Journal:  Mod Pathol       Date:  2008-06-20       Impact factor: 7.842

8.  MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Authors:  Tsuyoshi Iwata; Denise Schultz; Jessica Hicks; Gretchen K Hubbard; Laura N Mutton; Tamara L Lotan; Carlise Bethel; Matthew T Lotz; Srinivasan Yegnasubramanian; William G Nelson; Chi V Dang; MengMeng Xu; Uzoma Anele; Cheryl M Koh; Charles J Bieberich; Angelo M De Marzo
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

Review 9.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

10.  Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Authors:  Srinivas Nandana; Katharine Ellwood-Yen; Charles Sawyers; Marcia Wills; Brandy Weidow; Thomas Case; Valeri Vasioukhin; Robert Matusik
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.